Indicators of a hemostasis in patients with hyperhomocysteinemia on a hemodialysis
https://doi.org/10.20538/1682-0363-2011-1-127-131
Abstract
Inspection of 89 patients on a hemodialysis for the purpose of studying of feature hemostasiogram's indicators depending on level гомоцистеина is spent. At patients on a hemodialysis activation of intravascular curling of the blood, the most expressed at patients with hyperhomocysteinemia is revealed. Interrelation existence between concentration of homocysteine and hemostasiogram's indicators noted.
About the Authors
U. V. Kharlamova
Челябинская государственная медицинская академия
Russian Federation
Russian Federation
O. Ye. Ilyicheva
Челябинская государственная медицинская академия
Russian Federation
Russian Federation
References
1. Ильин А.П., Богоявленский В.Ф. Тромбофилия при гемодиализе у больных хронической почечной недостаточностью и ее фраксинопрофилактика и терапия: пособие для врачей. 2-е изд., испр. и доп. Казань, 2001. 32 с.
2. Манухина Е.Б., Малышев И.Ю. Роль оксида азота в сердечно-сосудистой патологии: взгляд патофизиолога // Рос. кардиолог. журн. 2000. № 5. С. 55—63.
3. Мойсюк Я.Г., Беляев А.Ю., Иноземцев А.С. и др. Постоянный сосудистый доступ для гемодиализа: современные тенденции // Нефрология и диализ. 2002. Т. 4, № 1. С. 14—24.
4. Bardic R., Rugerri Z.M., Savion N. et al. Platelet aggregation on extracellular matrix: effect of a recombination GPIbbinding fragment of von Willebrand factor // Thromb. Haemos. 1993. V. 70. P. 522—526.
5. Bennett-Richards K., Kattenhorn M., Donald A. et al. Total homocysteine levels and improve endothelial function in children with chronic renal failure? // Circulation. 2002. V. 105. P. 1810.
6. Blann A.D. Von Willebrand factor and the endothelium in vascular disease // Brit. J. Biomed. Sci. 1993. V. 50. P. 124—134.
7. Bostom A., Brosnan J.T., Hall B. Net uptake of plasma homocysteine by the rat kidney in vivo // Atherosclrrosis. 1995. V. 116. P. 59—62.
8. Cella G., Vertolli U., Naso A. et al. Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis // Thromb Res. 1996. V. 81. P. 671— 677.
9. Coen van Guldener. Why is homocysteine elevated in renal failure and what can be expected from homocysteinelowering? // Nephrology Dialysis Transplantation. 2006. V. 21, № 5. P. 1161—1166.
10. Friedman A.N., Bostom A.G., Selhub J. et al. The kidney and homocysteine metabolism // J. Am. Soc. Nephrol. 2001. V. 12. P. 2181—2189.
11. Genser D. Homocysteine, vitamins, and restenosis after percutaneous coronary intervention // Cardiovasc. Rev. Rep. 2003. V. 24, № 5. P. 253—258.
12. Harpel P.C., Zhang X., Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. // J. Nutr. 1996. V. 126, № 4. P. 1285—1289
13. Kanani P., Sinkey C., Browning R. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans // Circulation. 1999. V. 100. P. 1161—1168.
14. Lang D., Kredan M. B., Lang D., Moat S. J. et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: Role for superoxide anions // Arterioscler. Thromb. Vasc. Biol. 2000. V. 5. P. 257—261.
15. Loscalo J. The oxidant stress of hyperhomocyst(e)inemia // J. Clin. Invest. 1996. V. 98, № 1. P. 5—7.
16. Mayer E., Jacobsen D., Robinson K. Homocysteine and coronary atherosclerosis // J. Am. Coll. Cardiol. 1996. V. 27. P. 517—527.
17. Piolot A., Nadler F., Parez N., Jacotot B. L'homocysteine: ses liens avec les maladies cardiovasculaires ischemiques // Rev. Med. Interne. 1996. V. 17, № 1. P. 34—45.
18. Ruggery Z.M., Ware J., Ginsberg D. Von Willebrand factor // Thrombosis and Haemorrhage. 1994. V. 67. P. 305—329.
19. Sagripanti A., Cupisti A., Baicchi U. et al. Plasma parameters of the protrombotic state in chronic uremia // Nephron. 1993. V. 63. P. 273—278.
20. Stein J., McBride P. Hyperhomocysteinemia and atherosclerotic vascular disease // Arch. Intern. Med. 1998. V. 158. P. 1301—1306.
21. Suliman M.E., Divino Filho J.C., Barany P. et al. Effects of high-dose folic acid and pyridoxine on plasma and erythrocite sulfur amino acids in hemodialisis patients // J. Am. Soc. Nephrol. 1999. V. 10. P. 1287—1296.
22. Thambyrajah J., Landray M.J., McGlynn F.J. et al. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? // Circulation. 2000. V. 102. P. 871—875
23. Tawakol A., Forgione M., Stuehlinger M. et al. Homocysteine impairs coronary microvascular dilator function in humans // JACC. 2002. V. 40, № 6. P. 1051—1058.
24. Tawakol A., Omland T., Gerhard M. et al. Hyperhomocyst(e)inemia is associated with impaired endotheliumdependant vasodilatation in humans // Curculation. 1997. V. 95. P. 1119—1121.
25. Undas A., Williams B., Butenas S. et al. Homocysteine inhibits inactivation of factor Va by activated protein C // J. Biol. Chem. 2001. V. 276, № 6. P. 4389—4397.
26. Van Guldener C., Lambert J., Janssen M.J. et al. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients // Nephrol. Dial. Transplant. 1997. V. 12. P. 14—18
27. Vollset S.E., Refsum H., Ueland P.M. Population determinants of homocysteine // Am. J. Clin. Nutr. 2001. V. 73. P. 499—500
28. Wang J., Dudman N., Wilcken D. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells // Thromb. Haemost. 1993. № 70. Р. 1047—1052.
Review
For citations:
Kharlamova U.V., Ilyicheva O.Ye. Indicators of a hemostasis in patients with hyperhomocysteinemia on a hemodialysis. Bulletin of Siberian Medicine. 2011;10(1):127-131. (In Russ.) https://doi.org/10.20538/1682-0363-2011-1-127-131
Views:
445
Email this article 